| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/23/2005 | EP1597240A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof |
| 11/23/2005 | EP1597239A1 Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e) |
| 11/23/2005 | EP1597238A1 Hiv replication inhibiting pyrimidines and triazines |
| 11/23/2005 | EP1597236A1 Growth promotion method |
| 11/23/2005 | EP1597235A1 Non-nucleoside reverse transcriptase inhibitors |
| 11/23/2005 | EP1597234A2 Novel compounds |
| 11/23/2005 | EP1597230A1 Novel crystalline forms of trandolapril |
| 11/23/2005 | EP1597229A2 Pyrrolidine derivatives as oxytocin antagonists |
| 11/23/2005 | EP1597199A1 THERAPEUTIC MALONIC ACID/ACETIC ACID C sb 60 /sb TRI-ADDUCTS OF BUCKMINSTERFULLERENE AND METHODS RELATED THERETO |
| 11/23/2005 | EP1597171A2 Therapeutic microfoam |
| 11/23/2005 | EP1596884A2 Uses of integrin alphavbeta3 antagonists |
| 11/23/2005 | EP1596877A2 Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
| 11/23/2005 | EP1596876A1 Use of pvp-iodine liposomes for treatment of acne |
| 11/23/2005 | EP1596875A2 Tertiary amine functional complex polyester polymers and methods of production and use |
| 11/23/2005 | EP1596874A1 Method for treating liver cancer by intrahepatic administration of nemorubicin |
| 11/23/2005 | EP1596873A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 11/23/2005 | EP1596872A1 Compositions and methods for restoring bacterial flora |
| 11/23/2005 | EP1596871A2 T cell regulation |
| 11/23/2005 | EP1596870A1 High dose ibandronate formulation |
| 11/23/2005 | EP1596869A2 Novel cocrystallization |
| 11/23/2005 | EP1596868A1 Method for treating severe heart failure and medicament therefor |
| 11/23/2005 | EP1596867A2 Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| 11/23/2005 | EP1596866A2 Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| 11/23/2005 | EP1596865A1 Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain |
| 11/23/2005 | EP1596863A2 Pharmaceutical compositions for nasal delivery |
| 11/23/2005 | EP1596862A1 Use of palonosetron treating post-operative nausea and vomiting |
| 11/23/2005 | EP1596861A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 11/23/2005 | EP1596860A2 Novel compounds |
| 11/23/2005 | EP1596859A1 Treatment of diseases caused by ljungan virus by using pleconaril |
| 11/23/2005 | EP1596858A1 Ip receptor antagonists for the treatment of pathological uterine conditions |
| 11/23/2005 | EP1596857A2 Chroman-derived anti-androgens for the treatment of androgen-mediated disorders |
| 11/23/2005 | EP1596856A2 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds |
| 11/23/2005 | EP1596855A2 Methods and compositions for use in treating cancer |
| 11/23/2005 | EP1596854A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 11/23/2005 | EP1596853A1 Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions |
| 11/23/2005 | EP1596852A2 Drugs containing substituted 2-aryl-aminoacetic acid compounds |
| 11/23/2005 | EP1596851A1 The use of sodium 2-mercaptoethanesulfonate as antiviral agent |
| 11/23/2005 | EP1596850A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 11/23/2005 | EP1596849A1 Controlled release pharmaceutical compositions of tamsulosin |
| 11/23/2005 | EP1596848A1 Use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea for the treatment of pancreatic cancer, soft-tissue sarcoma, testicular tumors, lymphoma, thymoma, wilm's tumors, renal carcinoma, melanoma, lung cancer, intracerebral metastasis, tumors in the head and neck region, and mammary carcinoma |
| 11/23/2005 | EP1596847A1 New combination |
| 11/23/2005 | EP1596846A2 Inhibitors of hepatitis c virus, compositions and treatments using the same |
| 11/23/2005 | EP1596845A1 Therapeutic use of acyl glycerols and the nitrogen- and sulphur-containing analogues therof |
| 11/23/2005 | EP1596844A2 Use of sodium channel modulators for treating gastrointestinal tract disorders |
| 11/23/2005 | EP1596843A2 Slowly digestible starch |
| 11/23/2005 | EP1596842A2 Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| 11/23/2005 | EP1596839A2 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 11/23/2005 | EP1596837A2 Sustained release formulations of venlafaxine |
| 11/23/2005 | EP1596836A2 Sugar-free oral transmucosal solid dosage forms and uses thereof |
| 11/23/2005 | EP1596834A2 Microparticles comprising polynucleotides adsorbed on the surface of or entrapped within the microparticles |
| 11/23/2005 | EP1596828A2 Lipophilic drug delivery vehicle and methods of use thereof |
| 11/23/2005 | EP1596827A2 Use of pvp-iodine liposomes for treatment of herpes |
| 11/23/2005 | EP1596826A1 Use of pvp-iodine liposomes for treatment of atopic dermatitis |
| 11/23/2005 | EP1596825A2 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs |
| 11/23/2005 | EP1596824A1 Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
| 11/23/2005 | EP1596823A2 A stable ophthalmic composition |
| 11/23/2005 | EP1596822A2 A low dose corticosteroid composition |
| 11/23/2005 | EP1596821A2 Synergistic compositions and methods for potentiating anti-oxidative activity |
| 11/23/2005 | EP1596815A2 Composition and methods for inhibiting cell survival |
| 11/23/2005 | EP1596812A2 Bioadhesive liquid composition which is substantially free of water |
| 11/23/2005 | EP1596811A2 Compositions and methods to modulate immune and inflammatory responses |
| 11/23/2005 | EP1596810A2 Treatment of inflammatory bowel disease |
| 11/23/2005 | EP1596756A2 Absorption enhancing agents |
| 11/23/2005 | EP1596671A1 Chitosan foodstuff |
| 11/23/2005 | EP1596670A2 Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides |
| 11/23/2005 | EP1596656A2 Pyrazoles and methods of making and using the same |
| 11/23/2005 | EP1503754B1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| 11/23/2005 | EP1467718B1 Method of treatment of a patient requiring analgesia |
| 11/23/2005 | EP1463721B1 Compounds for imaging alzheimer's disease |
| 11/23/2005 | EP1444347B1 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
| 11/23/2005 | EP1408968B1 Receptor-adapted nicotine withdrawal by a combination of atropine, scopolamine, clonidine |
| 11/23/2005 | EP1377550B9 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors |
| 11/23/2005 | EP1372645B1 Reconstitutable parenteral composition containing a cox-2 inhibitor |
| 11/23/2005 | EP1343788B1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 11/23/2005 | EP1335898B1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| 11/23/2005 | EP1330226A4 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 11/23/2005 | EP1328276B1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 11/23/2005 | EP1320522B1 Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
| 11/23/2005 | EP1320372B1 Use of sulfatides for treating diabetes |
| 11/23/2005 | EP1296686B1 Praziquantel compositions for treating diseases caused by a coccidia |
| 11/23/2005 | EP1282430B1 Lipids for stimulation of immune response |
| 11/23/2005 | EP1280777B1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 11/23/2005 | EP1276497B1 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors |
| 11/23/2005 | EP1267846B1 Transdermal therapeutic system for the delivery of lerisetron |
| 11/23/2005 | EP1263802B1 Hydrogel biomedical articles |
| 11/23/2005 | EP1261254A4 Method of controlling zoological and aquatic plant growth |
| 11/23/2005 | EP1258249B1 Oral preparations for diabetes |
| 11/23/2005 | EP1250124B1 Slimming cosmetic composition comprising as active agent a plant extract containing a plant natriuretic peptide (pnp) |
| 11/23/2005 | EP1217983B1 Skincare composition against free radicals |
| 11/23/2005 | EP1183034B1 Modulators of methylation for control of bacterial virulence |
| 11/23/2005 | EP1165071B1 Improved cancer treatment with temozolomide |
| 11/23/2005 | EP1165066B1 Use of lipoxin compounds for inhibiting of tnf-alpha initiated neutrophil response |
| 11/23/2005 | EP1163528B1 Prediction of diabetes impaired wound healing |
| 11/23/2005 | EP1140291B1 Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor |
| 11/23/2005 | EP1140028B1 Biodegradable poly(phosphoester) compositions for treating ovarian cancer |
| 11/23/2005 | EP1117383B1 Dosage form comprising therapeutic formulation |
| 11/23/2005 | EP1112106B1 Serotonergic 5ht2 agonists for treating glaucoma |
| 11/23/2005 | EP1104294B8 Compositions and methods of treating abnormal cell proliferation |
| 11/23/2005 | EP1089739B1 Cyclophosphamide coated tablets |
| 11/23/2005 | EP1076559B1 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |